

# *The paradox of low BNP levels in obesity*

**Aldo Clerico, Alberto Giannoni, Simona Vittorini & Michele Emdin**

## **Heart Failure Reviews**

ISSN 1382-4147

Volume 17

Number 1

Heart Fail Rev (2012) 17:81-96

DOI 10.1007/s10741-011-9249-z



**Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author's version for posting to your own website or your institution's repository. You may further deposit the accepted author's version on a funder's repository at a funder's request, provided it is not made publicly available until 12 months after publication.**

## The paradox of low BNP levels in obesity

Aldo Clerico · Alberto Giannoni ·  
Simona Vittorini · Michele Emdin

Published online: 27 April 2011  
© Springer Science+Business Media, LLC 2011

**Abstract** The aim of this review is to analyze in detail some possible pathophysiological mechanisms linking obesity and cardiac endocrine function, in order to try to explain the negative association previously observed between BMI and BNP values in both healthy subjects and patients with cardiovascular diseases. In particular, we discuss the hypothesis that the response of the cardiac endocrine system is the integrated resultant of several and contrasting physiological and pathological interactions, including the effects of peptide and steroid hormones, cytokines, cardiovascular hemodynamics, clinical conditions, and pharmacological treatment. Several studies suggested that gonadal function regulates both body fat distribution and cardiac endocrine function. Visceral fat expansion can increase the clearance of active natriuretic peptides by means of an increased expression of clearance receptors on adipocytes, and in this way, it may contribute to decrease the activity of the cardiac endocrine system. Moreover, obesity is associated with ectopic lipid deposition even in the heart, which may directly exert a lipotoxic effect on the myocardium by secreting *in loco* several cytokines and adipokines. Obese subjects are frequently treated for hypertension and coronary artery disease. Pharmacological treatment reduces plasma level of cardiac natriuretic peptides, and this effect may explain almost in part the lower BNP levels of some asymptomatic subjects with increased BMI values. At present time, it is not

possible to give a unique and definitive answer to the crucial question concerning the inverse relationship between the amount of visceral fat distribution and BNP levels. Our explanation for these unsatisfactory results is that the cardiac endocrine response is always the integrated resultant of several pathophysiological interactions. However, only few variables can be studied together; as a result, it is not possible to perform a complete evaluation of pathophysiological mechanisms under study. We are still not able to well integrate these multiple information together; therefore, we should learn to do it.

**Keywords** BNP · NT-proBNP · Sex steroids · BMI · Obesity · Cardiovascular risk

### Background and article aim

The discovery of cardiac natriuretic hormones (CNH), namely atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), determined a radical conceptual revision of the heart function. CNH play a key role in the regulation of circulation and salt-water homeostasis and can exchange physiologically relevant information with other organs and systems.

Sarzani et al. [1, 2] suggested that obese individuals have an impaired natriuretic peptide response, and “natriuretic handicap” definition was used to describe this phenomenon. The existence of such a “handicap” was not definitively proven, although some experimental data suggest that ANP levels fail to rise appropriately in obese subjects after a saline load [3]. More recently, several studies have reported that circulating levels of BNP and its related peptide NT-proBNP are inversely related to body mass index (BMI) values in the general population [4, 5], as well as in patients

---

A. Clerico (✉) · A. Giannoni · S. Vittorini · M. Emdin  
Laboratory of Cardiovascular Endocrinology and Cell Biology,  
Fondazione CNR—Regione Toscana Gabriele Monasterio,  
Scuola Superiore Sant’Anna, Via Trieste 41, 56126 Pisa, Italy  
e-mail: clerico@ifc.cnr.it

A. Clerico · A. Giannoni  
Scuola Superiore S. Anna, Pisa, Italy

with heart failure (HF) [6–11]. These data seem to support the “natriuretic handicap hypothesis” indicating that the BNP levels are inappropriately low in obese subjects.


The main aim of this review is to analyze in detail some possible pathophysiological mechanisms linking obesity and cardiac endocrine function, in order to explain both the negative association, previously observed between increased BMI and BNP values in healthy subjects and patients with cardiovascular diseases. In particular, we discuss the hypothesis that the knowledge of the relationship between cardiac endocrine function and other neurohormonal and immune systems is crucial to accurately evaluate cardiovascular risk and mortality in all patients with cardiovascular disease, especially those with overweight or obesity.

### The endocrine cardiac function: a pathophysiological overture

CNH share potent diuretic, natriuretic, and vascular smooth muscle-relaxing effects, and they have complex

interactions with the hormonal and nervous systems [12, 13]. CNH are synthesized by cardiomyocytes as preprohormones (i.e., preproANP and perproBNP). In particular, human BNP is synthesized as a 134-amino acid (aa) precursor protein (preproBNP) and is subsequently processed during secretion to form a 108-aa peptide named proBNP (Fig. 1). The propeptide hormones of the cardiac natriuretic peptides can be enzymatically cleaved by proprotein convertases produced in the cardiomyocytes, such as corin and furin [14]. ProBNP is then processed to form the 76-aa N-terminal peptide (i.e., NT-proBNP) and the biologically active 32-aa C-terminal peptide (i.e., BNP). BNP has a shorter plasma half-life (about 15–20 min vs. 1 or 2 h) and consequently lower plasma concentration, compared with NT-proBNP. Moreover, the intact proBNP, an 108-aa peptide, is also present in plasma (especially of patients with heart failure) in both glycosylated and nonglycosylated form (Fig. 1) [14].

It is generally believed that ANP is preferentially produced in atria, while BNP in ventricles, particularly in patients with chronic cardiac diseases [13]. Synthesis and



**Fig. 1** Schematic representation of maturation and secretion of B-type-related natriuretic peptides by cardiomyocytes. Some of the biosynthesized pro-hormone (proBNP-108) is O-glycosylated within the Golgi apparatus. If O-glycosylation does not occur, proBNP-108 can be cleaved to BNP-32 and NT-proBNP-76 by the processing enzymes within the trans-Golgi network. If O-glycosylation occurs, glycosylated proBNP-108 cannot be cleaved, and unglycosylated

glycosylated proBNP-108 is secreted into the circulation. Finally, a smaller part of intact pro-hormone is not glycosylated and cleaved, and so this peptide can be present in circulation in intact form as proBNP-108. As indicated in the figure, the glycosylation on the threonyl residue in position 71 (Thr 71) could regulate pro-hormone cleavage by either blocking or guiding endoproteolytic enzymes (see reference [14] for more details)

secretion of the two peptides may be differently regulated in atrial versus ventricular cardiomyocytes, and, probably, during neonatal versus adult life [15–17]. The circulating levels of CNH are greatly increased in patients with cardiac disease, especially those with HF [13, 18, 19]. The measurement of B-type-related peptides is now considered a useful marker of myocardial function [13, 18–26]. Recent systematic reviews and meta-analyses demonstrated that both BNP and NT-proBNP assays have not only a high degree of diagnostic and prognostic accuracy in cardiovascular diseases [19–23] but also that BNP/NT-proBNP-guided therapy is able to significantly improve the outcome of patients with HF [27–29].

Wall stress (distension) is generally considered the main mechanical stimulus for BNP production by ventricular tissue (Fig. 2). However, mounting evidence from both in vivo and ex vivo studies is providing supports to the hypothesis that the production/secretion of CNH is regulated by complex interactions with neurohormonal and immune systems, especially in patients with cardiac disease [13, 14, 30–33]. Endothelin-1 and angiotensin II are considered the most powerful stimulators of production/secretion of both ANP and BNP; similarly, glucocorticoids, thyroid hormones, some growth factors, and especially some cytokines (such as TNF- $\alpha$ , interleukin-1, and interleukin-6) share stimulating effects on the cardiac endocrine function (Table 1 and Fig. 2) [13, 15, 16, 30–32]. Several studies indicate that BNP production/secretion may be differently regulated in the normal compared with the diseased ventricular myocardium [11, 30, 31, 34]. Indeed,

**Table 1** Some biological factors suggested to stimulate or inhibit the production/secretion of CNH in vivo or in cell culture of cardiomyocytes

Suggested stimulating factors
Angiotensin II
Endothelin-1
$\alpha$ -Adrenergic agents
Arginine vasopressin
Cytokines (including IL-1, IL-6, TNF- $\alpha$ )
Growth factors (such as fibroblast growth factor, FGFb, and transforming growth factor-b1, TGF b1)
Prostaglandins (such as PGF2 $\alpha$ and PGD2)
Lipopolysaccharide (LPS)
Chromogranin B
Thyroid hormones
Corticosteroids
Estrogens
Suggested inhibiting factors
Androgens
IGF-I
Nitric oxide (NO)

ventricular hypertrophy and especially the concomitant presence of mechanisms related to inflammation and fibrosis can stimulate BNP production in the diseased ventricular myocardium [34–36]. Furthermore, experimental and clinical studies indicated that also myocardial ischemia, and perhaps hypoxia, *per se*, could induce the synthesis/secretion of BNP and its related peptides by ventricular cells, even if isolated and cultured [33, 37–43] (Fig. 2).


### The Inverse Relationship between BNP and BMI

Obesity is a complex metabolic disorder, with an increasing epidemiologic impact in the European and the US population [44, 45]. BMI is usually considered to be a reliable index of overweight and obesity by some International Organizations, including the World Health Organization [44] and the National Institute of Health [45]. Several studies reported an inverse (negative) correlation between BMI and BNP/NT-proBNP values, both in healthy subjects and in patients with HF. In Table 2, we listed these studies, including some information regarding the study protocols and the main findings obtained. Although there is no doubt that an inverse correlation between BMI and BNP values is present, there is not a general consensus about the pathophysiological mechanisms responsible of this relationship. We will discuss in detail some pathophysiological mechanisms, suggested by different research groups in order to explain this relationship, in the following paragraphs.

#### Role of peripheral clearance and degradation of cardiac natriuretic peptides

The first proposed explanatory hypothesis for the inverse correlation between BMI and BNP values concerned a possible increase in the peripheral clearance of natriuretic peptides [7]. It is theoretically conceivable that an increased expression of the C-type natriuretic peptide receptor (NPR-C) in the adipose tissue, which has a clearance function on natriuretic peptides, may increase the peripheral removal of BNP throughout this specific way (Fig. 3) [7]. However, an increase in NPR-C in the adipose tissue should have no influence on NT-proBNP concentration, because this inactive peptide cannot bind this receptor. Recent data from our laboratory [46] confirmed that there are significant variations among groups of patients with different BMI, associated with a negative correlation between BMI and BNP values (Spearman rank correlation coefficient  $Rho = -0.240$ ,  $P < 0.0001$ ), as well as between BMI and NT-proBNP values ( $Rho = -0.243$ ,  $P < 0.0001$ ). Moreover, the ratio between





**Fig. 2** Highly schematic representation of regulation of BNP gene expression. BNP production may be affected by a huge number of neurohormones, cytokines, survival, and growth factors (see Table 1 for a complete list), as well as by mechanical strain and hypoxia. The stimulation (or inhibition) of the MAPK activity and the transcription factor NF- $\kappa$ B may play a relevant role in many of these regulatory pathways. As suggested in the Figure, neurohormones, cytokines, and other biological factors can regulate the CNH production throughout multiple and independent metabolic pathways, which can be activated

(or inhibited) in different pathophysiological conditions (see the references [13–17] for more details). As a result, the response of the cardiac endocrine system is the integrated resultant of several and contrasting physiological and pathological interactions, including the effects of peptide and steroid hormones, cytokines, cardiovascular hemodynamics, clinical conditions, and pharmacological treatment. *CPCR* G protein-coupled receptor, *HIF* hypoxia-inducible factor, *PCK* protein kinase C, *PI3K* phosphoinositide-3-kinase, *RTK*: receptor of tyrosine kinase

NT-proBNP and BNP values showed no significant variations among groups of patients with different BMI, thus suggesting that the clearance of BNP and NT-proBNP is similar among groups of HF patients with different BMI [46]. In conclusion, although an increased number of NPR-C into adipocyte membranes may contribute to decrease the BNP levels, it is very difficult that this increase may also play an important role in modulating the NT-proBNP levels in obese subjects.

However, some alterations in the peripheral turnover of CNH may exert a pathophysiological role. Higher amounts of unprocessed proBNP have been found in HF patients compared with healthy subjects [14, 47–52]. As a result, proBNP may be considered a circulating pro-hormone [14], which can be degraded into circulation to form the active peptide (i.e., BNP) by some plasma proteases, such as the enzymatic protein corin [53]. It is important to note that an impaired processing of proBNP in carriers of the corin I555

(P568) allele, almost exclusively expressed in individuals of African ancestry (allelic prevalence 6.7%), is associated with lower plasma BNP and with an increased cardiovascular risk as compared to noncarrier (control) subjects [54, 55]. In conclusion, some alterations of peripheral degradation of CNH may play a role also in the explanation of the lower BNP values observed in obese patients; however, further studies are necessary to test this hypothesis. In particular, the use of specific methods for the assay of unprocessed (intact) proBNP [48, 49, 52] will allow better knowledge of production/secretion as well as peripheral metabolism of B-type natriuretic peptide system, even in obese individuals and HF patients [56].

#### Role of sex steroid hormones

It is well known that development and distribution of body fat is closely regulated by gonadal function

**Table 2** Summary of study protocol and results of studies concerning the relationship between BMI and cardiac natriuretic peptides discussed in the review

Authors	Journal	Year of publication	Population studied	Study design	Main findings
Licata G et al. [3]	Hypertension	1994	Young normotensive obese human subjects	Experimental—saline load	Absence of ANP increase after intravascular volume expansion
Wang TJ et al. [4]	Circulation	2004	General population (from the Framingham study)	Cross sectional study—multivariate analysis	Lower BNP and N-ANP plasma levels in obese subjects (according to BMI)
Mehra MR et al. [6]	JACC	2004	Chronic HF population	Cross sectional study—multivariate analysis	Lower BNP in obese subjects (according to BMI)
McCord J et al. [10]	Arch Intern Med	2004	Patients presenting with acute dyspnea	Cross sectional study—multivariate analysis	Lower BNP values in obese subjects with or without HF, but BMI not independently related to BNP
Krauser DG et al. [9]	American Heart J	2005	Acute HF population	Cross sectional study—multivariate analysis	Lower BNP and NT-proBNP in obese subjects (according to BMI)
Das SR et al. [62]	Circulation	2005	General population (from the Dallas Heart Study)	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP/NT-proBNP with CNH more related to lean than fat mass
Kanda H et al. [113]	J Hum Hypertension	2005	General population (Japanese)	Cross sectional study—multivariate analysis	No significant correlation between BNP and BMI
Olsen MH et al. [136]	Hypertension	2005	General population (Danish)	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP/NT-proBNP
Daniels LB et al. [8]	American Heart J	2006	Human population of patients presenting with acute dyspnea	Cross sectional study—ROC analysis	Lower BNP cut-offs for diagnosis of HF in obese patients (defined by BMI)
Horwich TB et al. [107]	JACC	2006	Chronic HF population	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP
Taylor JA et al. [108]	Am J Cardiol	2006	Patients undergoing cardiac catheterization	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP, independently of left ventricular end diastolic pressure
van Kimmeneade R et al. [109]	JACC	2006	Patients undergoing bariatric surgery	Observational study—weight loss after surgery	Negative correlation between BMI and BNP/NT-proBNP, with CNH increase after BMI decrease following bariatric surgery
St Peter JV et al. [110]	Clin Chem	2006	Obese patient population	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP/NT-proBNP, with gastric bypass surgery predictor of increased BNP/NT-proBNP
Iwanaga Y et al. [111]	J Card Fail	2007	Chronic HF population	Cross sectional study—multivariate analysis	Negative correlation between BMI and BNP, independently of end diastolic wall stress parameters
Sarzani R et al. [1]	J Hypertension	2008	Cultures of human and in vitro-differentiated preadipocytes and visceral mature adipocytes	Experimental—exposure to ANP (and to angiotensin II)	Inhibition of cell growth by ANP (and stimulation by angiotensin II)
Park SJ et al. [11]	Korean Circ J	2009	Patients with chest pain and/or dyspnea undergoing cardiac catheterization	Cross sectional study—multivariate analysis	Negative correlation between BMI and NT-proBNP observed only in non diabetic patients

Table 2 continued


Authors	Journal	Year of publication	Population studied	Study design	Main findings
Pervanidou P et al. [112]	Horm Res Pediatr	2010	Healthy children	Cross sectional study— multivariate analysis	Lower NT-proBNP values in obese than non obese males, with no difference in females
Sugisawa T et al. [169]	Diabetes Res Clin Pract	2010	Patients with advanced type 2 diabetes	Cross sectional study— multivariate analysis	Negative correlation between BMI and BNP. BNP inversely related to visceral fat (from CT scan)
Chaimani-Wu N et al. [137]	Am J Cardiol	2010	Subjects with or at high risk of coronary artery disease	Observational study—weight loss after life-style modification	A decrease in BMI following lifestyle modifications is associated with BNP increase
Christenson RH et al. [105]	Clin Chem	2010	Patients presenting with dyspnea	Cross-sectional study— multivariate analysis	Negative correlation between BMI and NT-proBNP
Sugisawa T et al. [5]	Endocrinology J	2010	General population (Japanese)	Cross-sectional study— multivariate analysis	Lower BNP in obese subjects (according to BMI)

[57, 58]. Women have a higher percentage of body fat than men. Moreover, women tend to accumulate fat around the hips, buttocks, and thighs, while men have a larger intra-abdominal (visceral) fat mass. After menopause, there is a redistribution of fat depots, and postmenopausal women develop increased amounts of visceral fat [57]. This sex difference in body fat distribution was identified as the main determinant of the differing metabolic profiles and cardiovascular disease risk in men and women [57, 58]. Indeed, the risk of developing obesity-related diseases is significantly lower in premenopausal women compared to men, a difference that is abolished after menopause [57].

It was also suggested that the endocrine cardiac function is regulated by gonadal function [13, 46]. Indeed, BNP and NT-proBNP concentrations are low in the early years of extra-uterine life with similar values in both genders, while peptide levels increase progressively throughout the adolescence in girls, reaching the values in healthy premenopausal women about 2-fold higher than men at the same age [46, 59–61]. After 50 years of age, the difference in BNP and NT-proBNP values between sexes tends to decrease.

Several findings support the hypothesis that the gonadal function, and in particular the estrogens/androgens circulating ratio [46], may have a key role in the regulation of both body fat distribution and BNP production/secretion [62–65]. In women, estrogens may promote a gynoid distribution of body fat [58] and also increase the BNP production/secretion by cardiomyocytes [11, 46, 64, 65]. On the other hand, the results of the Dallas Heart Study [62, 63] suggested that androgens may regulate the cardiac endocrine function. Androgens may promote, at least in hyper-androgenic women, both the development of lean mass and the decrease in the natriuretic peptide production/secretion by cardiomyocytes. Moreover, the low circulating sex hormone-binding globulin (SHBG) levels found in women with abdominal obesity may indirectly indicate that elevated free androgens are related to increased visceral fat accumulation [58]. In men, androgens may increase cardiovascular risk because they promote a visceral (android type) fat distribution [58, 59], and they may also decrease the BNP production/secretion by cardiomyocytes [46]. However, data on androgen effects on cardiovascular risk in men are conflicting [66–75], probably because the relationship between testosterone concentrations and mortality risk is U-shaped [46, 58] with an increased risk for both high [68, 73, 74] and low [76–79] testosterone concentrations. Conversely, testosterone concentrations within the physiological range are usually associated with a more favorable metabolic profile and cardiovascular risk [58, 73].





**Fig. 3** Control of human fat cell lipolysis. Signal transduction pathways for catecholamines, for atrial natriuretic, and for insulin are summarized. In the top of the figure, the stimulating action of natriuretic peptides ANO, BNP, and CNP on adipocytes is shown. There are three known natriuretic peptide-specific receptors: **a** NPR-A, **b** NPR-B, and **c** NPR-C, also named clearance receptor. NPA-B and NPR-B contain an equally large intracellular signal domain catalyzing the synthesis of the intracellular signaling molecule cGMP. In contrast, NPR-C only contains a smaller residue intracellular domain and lacks guanylyl cyclase activity. It primarily controls local natriuretic peptide concentrations via receptor-mediated internalization and degradation. ANP, BNP, and CNP exert potent lipolytic effects in human fat cells, similar to those induced by the  $\beta$ -adrenoceptor agonist, isoproterenol, through a cGMP-dependent protein kinase signaling pathway independent of cAMP production. Intracellular cAMP concentrations are controlled by: (i) catecholamines through b-adrenoceptor-mediated adenylyl cyclase activation; (ii) inhibitory receptors (i.e.,  $\alpha_2$ -adrenoceptors, adenosine, prostaglandin, neuropeptide Y and peptide YY, and nicotinic acid) through the inhibition of adenylyl cyclase activity, and (iii) insulin through PDE-3B activation. CNH stimulate NPR-A-dependent guanylyl cyclase activity and cGMP production. cAMP and cGMP both contribute to the protein kinase [PKA and PKG (cGK-I)]-dependent

phosphorylation of HSL. Phosphorylation of HSL promotes translocation of HSL from the cytosol to the surface of the lipid droplet. PKA and PKG (cGK-I) phosphorylate several other substrates (enzymes and transcription actors, not shown in the diagram) and can also influence the secretion of various molecules from adipocytes. Stimulation of insulin receptors counteracts cAMP production by PDE-3B stimulation but has no effect on cGMP production. The products of the complete hydrolysis of triacylglycerols (i.e., NEFAs and glycerol) are released by fat cells. Docking of adipocyte lipid-binding protein (ALBP) to HSL favors the efflux of NEFA, whereas glycerol is channeled by aquaporin-7 (AQP-7), a water-glycerol transporter that is present in the plasma membrane. AC adenylyl cyclase, *A1* adenosine-R, *A1* adenosine receptor, *AR* adrenoceptor, *ATGL* adipose triglyceride lipase, *EP3-PGR* EP3 prostaglandin receptor, *Gi* inhibitory GTP-binding protein, *Gs* stimulatory GTP-binding protein, *GC* guanylyl cyclase, *HSL* hormone-sensitive lipase, *IRS-1* insulin receptor substrate 1, *MGL* monoacylglycerol lipase, *NEFA* nonesterified fatty acid, *NPY-Y1-R* type Y1 neuropeptide receptor, *PDE-3B* phosphodiesterase-3B, *PKA* protein kinase A, *PKB* protein kinase B (Akt), *PKG* (cGK-I) protein kinase G, *PtdIns3P-K* phosphatidylinositol-3-phosphate kinase, *PUMA-G* in mice, and *HM74-R* in humans, nicotinic acid receptor

#### Cross talk between endocrine function and adipose tissue: the role of adipokines

Recent findings support the hypothesis that the natriuretic peptide system (ANP, BNP, and, at a less extent, CNP) may have a role in the regulation of fat tissue function and development by exerting a potent lipolytic effect in human

fat cells [80–83]. On the other hand, obesity is associated with salt retention [84] and increased cardiac output [85, 86], which are mechanisms that should increase (rather than decrease) the activity of cardiac endocrine function [1, 2]. The hypothesis of “natriuretic handicap” [1, 2] implies that obesity is characterized by the presence of one or more circulating or tissue factors able to depress the

activity of cardiac endocrine function. In other words, this hypothesis assumes that there is a continuous cross talk between endocrine function and fat tissue.

A huge number of bioactive substances are increased in plasma of patients with obesity, such as noradrenaline, angiotensin II, vasopressin, endothelins, and some cytokines, which typically increase (rather than reduce) the production/secretion of CNH by cardiomyocytes (Table 1 and Fig. 2) [11–13, 15–17]. Also insulin was reported in one study to increase ANP secretion and gene expression in cultured rat cardiomyocytes, while glucose has no effect [87]. Therefore, all these neurohormones and pro-inflammatory factors should not be considered good candidates as the pathophysiological link between increased visceral fat distribution and low plasma BNP levels.

It is well known that obesity is associated with ectopic lipid deposition in multiple tissues, including the heart [88, 89]. It is now well accepted that fat tissue produces and secretes a great number of bioactive peptides (named adipokines), which act as mediators between obesity-related exogenous factors (nutrition and lifestyle) and the molecular events that lead to metabolic syndrome, inflammation, lipotoxicity, and cardiovascular diseases [90, 91]. A recent list of adipokines includes leptin, adiponectin, visfatin, apelin, vaspin, hepcidine, chemerin, and omentin [90].

It is interesting to note that some pro-inflammatory adipokines (such as leptin, resistin, and visfatin), like as some cytokines, are able to activate the transcription factor NF- $\kappa$ B [92–98], and subsequently by this pathway, they may stimulate the ANP and BNP gene transcription (Fig. 2). As a result, it may be hypothesized that these adipokines may stimulate the ANP and BNP gene transcription throughout this metabolic pathway. However, some very recent studies indicate a more complex effect of adipokines (such as leptin) on CNH production/secretion by cardiomyocytes. Mascareno et al. [99] reported that the antihypertrophic action of leptin *in vivo* may be mediated by CNH, since this action requires the activation of some transcription factors (such as NFATc4) followed by an increase in the expression of the ANP gene in mice. On the other hand, Yuan et al. [100] reported that leptin infusion inhibits ANP secretion indirectly through nitric oxide without changing basal or isoproterenol-induced ANP secretion in Sprague–Dawley rats. These studies suggest that CNH production/secretion by cardiomyocytes can be differently regulated by the same biological factor (such as leptin) throughout multiple metabolic pathways activated (or inhibited) in different pathophysiological conditions.

On the other hand, recent findings indicated that the CNH have a role in the regulation of fat tissue function and development [80]. Furthermore, several data indicated that CNH exert potent lipolytic effects in human fat cells,

similar to those induced by the  $\beta$ -adrenoceptor agonist, isoproterenol, through a cGMP-dependent protein kinase signaling pathway independent of cAMP production [83] (Fig. 3). Furthermore, ANP can increase the production of adiponectin [101], a polypeptide positively involved in glucose and free fatty acid metabolism (so to be protective from diabetes and metabolic syndrome), while the release of leptin is inhibited in culture of human adipocytes [102, 103]. These studies support the hypothesis that a continuous cross talk exists between cardiac endocrine function and adipose tissue system. From a pathophysiological point of view, further studies on the inter-relationship between CNH and adipokine systems may allow new insights into the link between metabolic disorders (such as diabetes mellitus, metabolic syndrome, and obesity), body fat distribution, and increased cardiovascular risk [46, 104].

Pathophysiological conditions and pharmacological treatment as possible confounding variables

Many studies found significantly reduced circulating levels of BNP and NT-proBNP in individuals with BMI values  $\geq 30$  kg/m<sup>2</sup> compared with individuals with normal BMI values, resulting an inverse (negative) association between BMI and plasma BNP and NT-proBNP values [4, 5, 8–11, 62, 63, 105–112] (Table 2). Some studies were based on large population [4, 5, 62, 63, 106], including both healthy adult subjects and patients with various disorders (only patients with HF were excluded), while other studies included only patients with HF [8–11, 105] (Table 2). However, conflicting results were also reported; Kanda et al. [113] found no significant correlation between BNP to BMI values in a general Japanese population, including 686 apparently healthy subjects.

Overweight and obese individuals show an increased mortality risk and for this reason are more frequently treated for hypertension, coronary artery disease, or other cardiovascular disorders than lean subjects [114]. It is well known that ACE inhibitors, angiotensin receptor blockers (such as valsartan), diuretics, and nitrates are able to reduce plasma CNH levels in parallel with hemodynamic and clinical improvement [19, 27]. Moreover, although acute administration of some  $\beta$ -blockers may provide an early rise in plasma CNH, sustained treatment is associated with improvement in cardiac function, reduction in filling pressure, cardiac volumes, and a fall in CNH levels [19]. The decrease in plasma BNP and NT-proBNP under baseline median concentration is associated with treatment efficacy and clinical improvement, whereas unchanged or increased levels are associated with disease progression and worse prognosis [115, 116]. Some recent meta-analyses demonstrated that if BNP-guided treatment is able to significantly decrease the peptide levels, it is also effective

on prognosis [27, 28, 117]. In other words, treated patients who have low BNP/NT-proBNP values also have a lower mortality risk independently of other predictive variables (including the presence of obesity or metabolic syndrome).

From a theoretical point of view, pharmacological treatment for cardiac disease should be considered a possible candidate as the pathophysiological link between increased visceral fat distribution and low CNH levels. Indeed, patients at high risk (such as those with obesity, hypertension, and/or type-2 diabetes mellitus) are more frequently treated, and an efficacious treatment significantly reduces plasma BNP and NT-proBNP levels.

From a statistical point of view, the confounding effect of pharmacological treatment is difficult to estimate in a multivariable statistical analysis [118]. Indeed, type, dose, association, and interaction of drugs administered greatly vary among patients with cardiovascular diseases. Furthermore, pharmacological treatment is generally evaluated in multiple regression analyses as a dichotomized variable. Dichotomization produces loss of information, reduces statistical power, and introduces the possibility of erroneous results [119, 120]. Finally, several recent studies and meta-analyses have demonstrated that treatment response is clinically more relevant than the treatment itself in HF patients [19, 27, 28, 115–117]. An effective response to treatment is strongly dependent by clinical conditions: severe disease, old age, and presence of comorbidities are associated with both no response to treatment and higher mortality risk in HF patients [19, 26–29, 115–117]. These two variables (clinical condition and pharmacological treatment), being greatly variable among patients enrolled in the same population study and even more in different studies, may actually produce some conflicting results.

Role of possible confounding variables: are all individuals with  $\text{BMI} \geq 30 \text{ kg/m}^2$  true obese?

Overweight is usually defined as a BMI of 25–29.9  $\text{kg/m}^2$ , while obesity as a BMI of  $\geq 30 \text{ kg/m}^2$  [44, 45]. BMI is a simple, common parameter for rating obesity level, but it may be misleading in some specific clinical conditions, because it is not able to assess the distribution of major components of body weight: fat, lean body mass, and fluid body content [121]. Indeed, BMI overestimates body fat in people who are very muscular (such as bodybuilders and athletes) or who have edema [122] and in young adult males compared to young adult females, because of the lesser percent body fat in men. As an example, in 1970, Arnold Schwarzenegger at age 23, when he won the Mr. Olympia contest for the first time, had a body weight of 113 kg and a height of 1.88 m [123], with a corresponding BMI of 32.0  $\text{kg/m}^2$ ; consequently, according to these data, we should assume that an obese men won the most

important bodybuilder contest in 1970. Conversely, BMI underestimates body fat in people with muscle mass loss, such as the elderly.

Due to these BMI limitations, there is need to take into account more accurate investigations of major components of body weight (such as DEXA or computed tomography and magnetic resonance imaging) [124, 125], in order to understand the relationship linking circulating natriuretic peptides and sex steroid hormones to fat distribution and body weight. The results of large population studies, discussed above, which used only BMI for estimation of obesity [4–6, 8–11, 105, 106, 113, 114], should be taken into consideration only after an accurate analysis of the anthropometric characteristics of the individuals enrolled in the study. In the following paragraph, we will discuss more in detail the pathophysiological and clinical implication of this important issue.

Role of possible confounding variables: difference in analytical performance of BNP and NT-proBNP immunoassays

There is another possible important confounding variable in the evaluation and comparison of different studies on cardiac natriuretic peptides. It is well known that there are significant differences in the analytical characteristics and clinical results (including differences in reference ranges, decision levels, and cutoff values) among immunoassays for B-type-related peptides, and these differences might allow misleading clinical interpretation [126–128], as also recently confirmed by a multicentre study [129]. Since BNP and NT-proBNP have completely different biochemical structure, molecular weight, biological activity, and degradation pathways, it is not surprising that immunoassay methods considered specific for BNP or NT-proBNP show different analytical characteristics, quality specifications, and measured values [126–129]. However, the CardioOrmocheck study [129] has recently confirmed that there are large differences (up to 2.7-fold) even in measured values between the results obtained with the most popular fully automated platforms considered specific for BNP immunoassays, while less differences are found between the most popular fully automated platforms for NT-proBNP assay. These results are largely expected because all the commercial NT-proBNP methods actually use antibodies and standard materials from the same source (i.e., Roche Diagnostics), while BNP methods use different antibodies and standard materials [127–129]. These differences in measured values are probably due to relative poor specificity of all commercial assays for BNP and NT-proBNP peptides, due to presence of a significant cross-reactivity with the intact precursor proBNP<sub>1-108</sub>, variable for each assay [130]. Unfortunately, at present time, it very

difficult to estimate the exact influence of proBNP in the BNP and NT-proBNP immunoassays, because there are no commercial methods specifically designed for the measurement of intact proBNP. These data suggest that the great part of peptides measured with commercial immunoassays for B-type natriuretic hormone probably is inactive peptides present in plasma samples (Fig. 1), and so the measurement of BNP may be an unreliable index of the true biological activity of the cardiac endocrine function [13, 14].

### BNP levels, obesity, and mortality risk in patients with heart failure

Two recent meta-analyses confirmed that overweight and obesity, as assessed by BMI, are associated with lower (rather than higher) all-cause and cardiovascular mortality rate in patients with congestive HF [122, 124]. These findings are consistent with other evidences in different chronic disease populations, which demonstrate improved mortality with higher BMI levels [125, 131–133]. This phenomenon, termed “reverse epidemiology” and involving about 20 million Americans, may be due to the overwhelming effect of the malnutrition–inflammation complex syndrome (MICS) [131]. The presence of MICS in some patients contributes to explain the inverse correlation between BMI and BNP values in HF [6, 8–11, 105]. BNP production/secretion is greatly increased in elderly HF patients with severe disease, hemodynamic impairment, and activation of counteracting neurohormone (including adrenergic, renin–angiotensin–aldosterone, and endothelin) and cytokine systems compared to asymptomatic subjects [13, 30–35]. On the other hand, BMI is significantly decreased in chronic HF patients with anorexia, malnutrition, and body wasting [131]. These patients usually show increased circulating levels of some cytokines (especially TNF- $\alpha$ ), able to activate cardiac endocrine function, and have also more severe clinical disease and very poor prognosis [13, 30, 31, 134]. Furthermore, it is well known that androgen production is decreased in elderly male subjects and patients with severe chronic disease [135]; in turn, this condition may contribute to increase the production of CNH [46].

A huge number of studies reported the clinical usefulness of CNH as prognostic biomarker for all-cause and cardiovascular mortality both in the general population [136–143] and in patients with cardiovascular diseases [144–155]. Furthermore, several meta-analyses confirmed that BNP/NT-proBNP assay is a powerful prognostic marker in the general population, as well as in patients with cardiac diseases or undergoing cardiac and noncardiac surgery [19, 156–160]. These studies usually suggest that

the mortality risk progressively increases according to the rise in plasma BNP and NT-proBNP concentration and also that there is no threshold value below which there is no risk [19, 156, 161]. In other words, the risk of death and cardiovascular events seems to rise even for small increments of BNP values in patients with HF [156], thus suggesting that to have low BNP values is always “a good thing” owing to the association with lower mortality risk.

In conclusion, high baseline BNP and NT-proBNP values and especially significant increased (or unchangeable) values with respect to baseline levels after treatment (i.e., no response to treatment) are powerful and independent (to other predictive variables, including obesity and metabolic syndrome) prognostic markers of all-cause and cardiovascular mortality risk in patients with HF [27, 115, 116], which is the natural and final end of all cardiovascular diseases [162]. As a result, this finding seems to be, almost in part, in conflict with the “natriuretic handicap” original hypothesis [1, 2, 7], which predicts that obese patients (characterized by lower plasma BNP and NT-proBNP values) should have an increased (rather than decreased) cardiovascular and mortality risk compared to lean individuals (characterized by higher peptide values).

### Prospective remarks

At present time, it is not possible to give a definitive answer to the crucial question what the pathophysiological link between increased visceral fat distribution and low plasma BNP levels is. However, we would like to suggest some indications in order to restrict and to better direct the future researches in this field.

- (1) While BMI is a simple, common parameter for rating obesity level [44, 45], it may be misleading in some specific clinical conditions [122, 123]. Due to these limitations concerning BMI, we need further studies using more accurate investigations of major components of body weight (such as DEXA or computed tomography and magnetic resonance imaging), in order to better understand the relationship linking CNH and body fat distribution [163].
- (2) Obese individual or patients with metabolic syndrome are frequently treated for comorbidity or cardiovascular complications, such as hypertension, coronary artery disease, or other cardiac disorders. The standard pharmacological treatment tends to decrease the production/secretion of CNH. As a result, treated patients usually show lower plasma BNP and NT-proBNP than untreated individuals (lean or obese). The pharmacological treatment is usually considered a stubborn bias factor in multivariate analyses [118],



which should be taken specifically into account as possible confounding factor in future epidemiological or clinical studies evaluating the link between CNH system and body fat distribution.

- (3) The response of the CNH system is always the integrated resultant of several and contrasting physiological and pathological interactions [13]. Although fascinating, the hypothesis that gonadal function regulates both body fat distribution and cardiac endocrine function needs further evidence. In particular, it is necessary the conclusive demonstration that sex steroids (especially androgens) are able to actually affect (increase or decrease) the production/secretion of BNP from mammalian (including human) cardiomyocytes both in cell cultures and in vivo [46]. Moreover, visceral fat expansion can increase the clearance of active natriuretic peptides (ANP and BNP) by means of an increased expression of NPR-C on adipocytes, and in this way, it may contribute, almost in part, to decrease the activity of the CNH system [1, 7]. Obesity is associated with ectopic lipid deposition even in the heart, which may directly exert a lipotoxic effect on the myocardium by secreting *in loco* several cytokines and adipokines. These substances can affect both the endocrine and the contractile function cardiomyocytes throughout a paracrine effect [88, 89]. We believe that future studies should be set up to evaluate especially this important issue: the possible effects of some specific adipokines on CNH system.
- (4) Most diseases are the consequence of the breakdown of cellular processes, but the relationships among genetic/epigenetic defects, the molecular interaction networks underlying them, and the disease phenotypes remain poorly understood. The network concept may reveal a number of surprising connections among different clinical conditions [164–166]. Similarly, the effects of drugs are not limited to the molecules they directly bind to; instead, these effects can spread throughout the cellular network in which they act, causing unwanted side effects [165]. Furthermore, the more connected a disease is to other diseases, the higher is its prevalence and associated mortality rate [167].

In an integrated communicative network, several actors can play a role throughout several positive or negative feedback servomechanisms. A network topology-based approach may help to uncover potential mechanisms that contribute to cardiovascular diseases [167]. Peptide and steroid hormones, cytokines, cardiovascular hemodynamics, clinical conditions, and pharmacological treatment may all together contribute to the pathophysiological

mechanisms linking endocrine function regulation and body fat growth and distribution. The response of the CNH system is always the integrated resultant of all these pathophysiological interactions. However, only few variables of a biological system are usually studied together. As a result, a lot of information is not taken into consideration, and so it is impossible to have an accurate interpretation and evaluation of all pathophysiological mechanisms under study. Unfortunately, we are still not able to well integrate these multiple information together [168]; therefore, we should learn to do it.

## References

1. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A (2008) Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, hypertension: an integrated view in humans. *J Hypertens* 26:831–843
2. Sarzani R, Marcucci P, Salvi F, Bordicchia M, Espinosa E, Mucci L et al (2008) Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. *Int J Obes* 32:259–267
3. Licata G, Volpe M, Scaglione R, Rubattu S (1994) Salt-regulating hormones in young normotensive obese subjects: effects of saline load. *Hypertension* 23(1 Suppl):I20–I24
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW et al (2004) Impact of obesity on plasma natriuretic peptide levels. *Circulation* 109:594–600
5. Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y, Yoshimasa Y (2010) Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study. *Endocr J* 57:727–733
6. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC et al (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. *J Am Coll Cardiol* 43:1590–1595
7. Dessì-Fulgheri P, Sarzani R, Rappelli A (1998) The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. *J Nephrol* 11:296–299
8. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J et al (2006) How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the breathing not properly multinational study. *Am Heart J* 151:999–1005
9. Krauser D, Lloyd-Jones D, Chae C, Cameron R, Anwaruddin S, Baggish AL et al (2005) Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy. *Am Heart J* 149:744–750
10. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT et al (2004) Breathing not properly multinational study investigators. Relationship between obesity and B-type natriuretic peptide levels. *Arch Intern Med* 164:2247–2252
11. Park SJ, Cho KI, Jung SJ, Choi SW, Choi JW, Lee DW et al (2009) N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. *Korean Circ J* 39:538–544
12. De Bold AJ (1985) Atrial natriuretic factor: a hormone produced by the heart. *Science* 230:427–470
13. Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic



- regulation network: physiological and clinical implications. *Am J Physiol Heart Circ Physiol* 290:H17–H29
14. Goetze JP (2010) Biosynthesis of cardiac natriuretic peptides. *Results Probl Cell Differ* 50:12–97
  15. De Bold AJ, Bruneau BG, Kuroski de Bold ML (1996) Mechanical and neuroendocrine regulation of the endocrine heart. *Cardiovasc Res* 31:7–18
  16. De Bold AJ, Ma KKY, Zhang Y, Kuroski de Bold ML, Bensimon M, Khoshbaten A (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. *Can J Physiol Pharmacol* 79:705–714
  17. McGrath MF, de Bold AJ (2005) Determinants of natriuretic peptide gene expression. *Peptides* 26:933–943
  18. Balion CM, Santaguida P, McKelvie R, Hill SA, McQueen MJ, Worster A et al (2008) Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. *Clin Biochem* 41:231–239
  19. Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. *Clin Chem* 50:33–50
  20. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ (2004) A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. *Arch Intern Med* 164:1978–1984
  21. Clerico A, Fontana M, Zyw L, Passino C, Emdin M (2007) Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. *Clin Chem* 53:813–822
  22. Balion CM, McKelvie RS, Reichert S, Santaguida P, Booker L, Worster A et al (2008) Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool? *Clin Biochem* 41:266–276
  23. Ewald B, Ewald D, Thakkinstian A, Attia J (2008) Meta-analysis of B type natriuretic peptide, N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure, population screening for left ventricular systolic dysfunction. *Intern Med J* 38:101–113
  24. Emdin M, Passino C, Prontera C, Fontana M, Poletti R, Gabutti A, Mammini C, Giannoni A, Zyw L, Zucchelli GC, Clerico A (2007) Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. *Clin Chem* 53:1264–1272
  25. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL et al (2007) National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. *Circulation* 116:e99–e109
  26. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. *Eur Heart J* 29:2388–2442
  27. Clerico A, Fontana M, Ripoli A, Emdin M (2009) Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. *Adv Clin Chem* 48:163–179
  28. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. *Am Heart J* 158:422–430
  29. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K et al (2010) Clinical trials of pharmacological therapies in acute heart failure syndromes. Lessons learned and directions forward. *Cir Heart Fail* 3:314–325 (on behalf of the International AHFS Working Group)
  30. Ramos H, de Bold AJ (2006) Gene expression, processing, and secretion of natriuretic peptides: physiologic and diagnostic implications. *Heart Fail Clin* 2:255–268
  31. De Bold AJ (2009) Cardiac natriuretic peptides gene expression and secretion in inflammation. *J Investig Med* 57:29–32
  32. Kuwahara K, Nakao K (2010) Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. *Endocr J* 57:555–565
  33. Goetze JP, Georg B, Jørgensen HL, Fahrenkrug J (2010) Chamber-dependent circadian expression of cardiac natriuretic peptides. *Regul Pept* 160:140–145
  34. Sakata Y, Yamamoto K, Masuyama T, Mano T, Nishikawa N, Kuzuya T et al (2001) Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. *J Hypertens* 19:1905–1959
  35. Takahashi N, Saito Y, Kuwahara K, Harada M, Kishimoto I, Ogawa Y et al (2003) Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. *Hypertens Res* 26:847–853
  36. Walther T, Klostermann K, Heringer-Walther S, Schultheiss HP, Tschope C, Stepan H (2003) Fibrosis rather than blood pressure determines cardiac BNP expression in mice. *Regul Pept* 116:95–100
  37. Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J et al (1994) Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. *Am J Physiol* 266:H1572–H1580
  38. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y et al (1995) Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. *Circulation* 92:1158–1164
  39. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB (2004) Acute myocardial hypoxia increases BNP gene expression. *FASEB J* 18:1928–1930
  40. Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P et al (2004) Natriuretic peptides in unstable coronary artery disease. *Eur Heart J* 25:1486–1493
  41. Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, Jiménez W (2009) Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. *Am J Physiol Heart Circ Physiol* 297:H550–H555
  42. Chiu CZ, Wang BW, Chung TH, Shyu KG (2010) Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes. *Clin Sci* 119:273–282
  43. Tan T, Scholz PM, Weiss HR (2010) Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. *Lige Sci* 80:9–16
  44. Preventing and Managing the Global Epidemic of Obesity (1997) Report of the world health organization consultation of obesity. WHO, Geneva
  45. Pi-Sunyer FX, Becker DM, Bouchard C, Colditz GA, Carleton RA, Dietz WH et al. (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Heart, Lung and Blood Institute
  46. Clerico A, Fontana M, Vittorini S, Emdin M (2009) The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. *Clin Chim Acta* 405:1–7
  47. Goetze JP (2004) Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. *Clin Chem* 50:1503–1510
  48. Goetze JP, Rehfeld JF (2009) Peptide hormones and their pro-hormones as biomarkers. *Biomark Med* 3:335–338

49. Giuliani I, Rieunier F, Larue C, Delagneau JF, Granier C, Pau B et al (2006) Assay for measurement of intact B-type natriuretic peptide prohormone in blood. *Clin Chem* 52:1054–1561
50. Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, Clopton P, Fitzgerald RL et al (2008) Pro-B-type natriuretic peptide levels in acute decompensated heart failure. *J An Coll Cardiol* 51:1874–1882
51. Wu AH, Smith A, Rame E, Wians F, Minard F, Giuliani I et al (2009) Analytical assay characterization for 1–108 pro-B-type natriuretic peptide on the BioPlex 2200 analyzer. *Clin Chim Acta* 408:143–144
52. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP (2010) Simultaneous Assessment of Unprocessed ProBNP1–108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. *Circ Heart Fail* 3: 220–227
53. Peleg A, Jaffe AS, Hasin Y (2009) Enzyme-linked immuno absorbent assay for detection of human protease corin in blood. *Clin Chim Acta* 409:85–89
54. Rame JE, Drazner MH, Post W, Peshock R, Lima J, Cooper RS et al (2007) Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. *Hypertension* 49:857–864
55. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH et al (2009) Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the genetic risk assessment in heart failure sub study. *Circ Heart Fail* 2:541–548
56. Emdin M, Passino C, Clerico A (2011) Natriuretic peptide assays revisited. Do we need proB-type natriuretic peptide? *J Am Coll Cardiol* 57:1396–1398
57. Mattsson C, Olsson T (2007) Estrogens and glucocorticoid hormones in adipose tissue metabolism. *Curr Med Chem* 14: 2918–2924
58. Blouin K, Boivin A, Tchermof A (2008) Androgens and body fat distribution. *J Steroid Biochem Mol Biol* 108:272–280
59. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D (2002) Circulating levels of cardiac natriuretic hormones in healthy adult subjects: effects of aging and sex. *Clin Chem Lab Med* 40:371–377
60. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L et al (2009) NT-Pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. *Pediatr Cardiol* 30:3–8
61. Cantinotti M, Storti S, Parri MS, Prontera C, Murzi B, Clerico A (2010) Reference intervals for brain natriuretic peptide in healthy newborns and infants measured with an automated immunoassay platform. *Clin Chem Lab Med* 48:697–700
62. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM et al (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas heart study. *Circulation* 112:2163–2168
63. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK et al (2007) Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas heart study. *J Am Coll Cardiol* 49:109–116
64. Kuroski de Bold ML (1999) Estrogen, natriuretic peptides and the renin-angiotensin system. *Cardiovasc Res* 41:524–531
65. Maffei S, Del Ry S, Prontera C, Clerico A (2001) Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. *Clin Sci* 101:447–453
66. Elbers JM, Asscheman H, Seidell JC, Gooren LJ (1999) Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. *Am J Physiol* 276:E317–E325
67. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ (1997) Long-term testosterone administration increases visceral fat in female to male transsexuals. *J Clin Endocrinol Metab* 82:2044–2047
68. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC et al (2003) Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. *Clin Endocrinol* 58:562–571
69. Boyanov MA, Boneva Z, Christov VG (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. *Aging Male* 6:1–7
70. Marin P (1995) Testosterone and regional fat distribution. *Obes Res* 3(Suppl. 4):609S–612S
71. Schroeder ET, Zheng L, Ong MD, Martinez C, Flores C, Stewart Y et al (2004) Effects of androgen therapy on adipose tissue, metabolism in older men. *J Clin Endocrinol Metab* 89: 4863–4872
72. Lovejoy JC, Bray GA, Greenson CS, Klemperer M, Morris J, Partington C et al (1995) Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. *Int J Obes Relat Metab Disord* 19:614–624
73. Blouin K, Després JP, Couillard C, Tremblay A, Prud'homme D, Bouchard C et al (2005) Contribution of age and declining androgen levels to features of the metabolic syndrome in men. *Metabolism* 54:1034–1040
74. Glazer G (1991) Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. *Arch Intern Med* 151: 1925–1933
75. Phillips GB, Jing T, Heymsfield SB (2003) Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. *Metabolism* 52:784–790
76. Traish AM, Saad F, Guay A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. *J Androl* 30:23–32
77. Traish AM, Saad F, Feeley RJ, Guay A (2009) The dark side of testosterone deficiency: III. Cardiovascular disease. *J Androl* 30:477–494
78. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P (2008) Hypogonadotropic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. *Curr Mol Med* 8:816–828
79. Zitzmann M (2009) Testosterone deficiency, insulin resistance and the metabolic syndrome. *Nat Rev Endocrinol* 5:673–681
80. Costello-Boerrigter LC, Burnett JC Jr (2009) A new role for the natriuretic peptides: metabolic regulators of the adipocyte. *J Am Coll Cardiol* 53:2078–2079
81. Garruti G, Giusti V, Nussberger J, Darimont C, Verdumo C, Amstutz C et al (2007) Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes. *Obesity* 15:2181–2189
82. Sengenès C, Zakaroff-Girard A, Moulin A et al (2002) Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. *Am J Physiol Regul Integr Comp Physiol* 283:R257–R265
83. Lafontan M, Moro C, Berlan M, Crampes F, Sengenès C, Galitzky J (2008) Control of lipolysis by natriuretic peptides and cyclic GMP. *Trends Endocrinol Metab* 19:130–137
84. Licata G, Volpe M, Scaglione R, Rubattu S (1994) Salt-regulating hormones in young normotensive obese subjects: effects of saline load. *Hypertension* 23(1 Suppl):I20–I124
85. Messerli FH, Ventura HO, Reisin E, Dreslinski GR, Dunn FG, MacPhee AA et al (1982) Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. *Circulation* 66:55–60

86. Emdin M, Gastaldelli A, Muscelli E, Macerata A, Natali A, Camastra S et al (2001) Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. *Circulation* 103:513–519
87. Tokudome T, Horio T, Yoshihara F, Suga S, Kawano Y, Kohno M et al (2004) Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. *Metabolism* 53: 710–715
88. Wende AR, Abel ED (2010) Lipotoxicity in the heart. *Biochim Biophys Acta* 1801:311–319
89. Shimabukuro M (2010) Cardiac adiposity and global cardio metabolic risk. New concept and clinical implications. *Circ J* 73:27–34
90. Gualillo O, Gonzalez-Juanately JR, Lago F (2007) The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. *Trends Cardiovasc Med* 17:275–283
91. Wozniak SE, Gee LL, Wachtel MS, Frezza EE (2009) Adipose tissue: the new endocrine organ? A review article. *Dig Dis Sci* 54:1847–1856
92. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ (2005) Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. *Biochem Biophys Res Commun* 334:1092–1101
93. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päiväranta U, Moilanen T et al (2009) Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage—mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. *Mediators Inflamm* 2009:345838
94. Mattioli B, Giordani L, Quaranta MG, Viora M (2009) Leptin exerts an anti-apoptotic effect on human dendritic cells via the PI3 K-Akt signaling pathway. *FEBS Lett* 583:1102–1106
95. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC et al (2008) Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3 K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. *Cell Signal* 20:1478–1488
96. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E et al (2005) Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. *Hepatology* 42:1339–1348
97. Lappas M, Permezel M, Rice GE (2005) Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. *Endocrinology* 146:3334–3342
98. Adya R, Tan BK, Chen J, Randeve HS (2008) Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. *Diabetes Care* 31:758–760
99. Mascareno E, Beckles D, Dhar-Mascareno M, Siddiqui MA (2009) Enhanced hypertrophy in ob/ob mice due to an impairment in expression of atrial natriuretic peptide. *Vascul Pharmacol* 51:198–204
100. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ et al (2010) Leptin reduces plasma ANP level via nitric oxide-dependent mechanism. *Am J Physiol Regul Integr Comp Physiol* 298: R1007–R1016
101. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A et al (2009) Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. *J Am Coll Cardiol* 53:2070–2077
102. Fain JN, Kanu A, Bahouth SW, Cowan GS, Lloyd Hiler M (2003) Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. *Biochem Pharmacol* 65:1883–1888
103. Moro C, Klimcakova E, Lolmède K, Berlan M, Lafontan M, Stich V et al (2007) Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. *Diabetologia* 50:1038–1047
104. Canoy D (2010) Coronary heart disease and body fat distribution. *Curr Atheroscler Rep* 12:125–133
105. Christenson RH, Azzazy HM, Duh SH, Maynard S, Seliger SL, Defilippi CR (2010) Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. *Clin Chem* 56:633–641
106. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW et al (2002) Impact of age and sex on plasma natriuretic peptide levels in healthy adults. *Am J Cardiol* 90:254–258
107. Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. *J Am Coll Cardiol* 47:85–90
108. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS (2006) B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. *Am Heart J* 152:1071–1076
109. van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, Pinto YM (2006) Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? *J Am Coll Cardiol* 48:1621–1627
110. St Peter JV, Hartley GG, Murakami MM, Apple FS (2006) B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. *Clin Chem* 52:680–685
111. Iwanaga Y, Kihara Y, Niizuma S, Noguchi T, Nonogi H, Kita T, Goto Y (2007) BNP in overweight and obese patients with heart failure: an analysis based on the BNP-LV diastolic wall stress relationship. *J Card Fail* 13:663–667
112. Pervanidou P, Akalestos A, Sakka S, Kanaka-Gantenbein C, Papassotiropoulos I, Chrousos GP (2010) Gender dimorphic associations between N-terminal pro-brain natriuretic peptide, body mass index and blood pressure in children and adolescents. *Horm Res Paediatr* 73:341–348
113. Kanda H, Kita Y, Okamura T, Kadowaki T, Yoshida Y, Nakamura Y et al (2005) What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population? *J Hum Hypertens* 19:165–172
114. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. *Circulation* 115:1345–1353
115. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L et al (2006) Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. *Am J Med* 119:70.e23–70.e30
116. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T et al (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). *J Am Coll Cardiol* 52:997–1003
117. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide—guided heart failure therapy. A meta-analysis. *Arch Int Med* 170:507–514
118. Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN et al (2010) A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol* 63:64–74

119. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. *Stat Med* 25:127–141
120. Altman DG, Royston P (2006) The cost of dichotomising continuous variables. *Br Med J* 332:1080
121. Lee SY, Gallagher D (2008) Assessment methods in human body composition. *Curr Opin Clin Nutr Metab Care* 11:566–572
122. Shirley S, Davis LL, Carlson BW (2007) The relationship between body mass index/body composition and survival in patients with heart failure. *J Am Acad Nurse Pract* 20:326–332
123. Wikipedia, the free encyclopedia. Arnold Alois Schwarzenegger. ([http://en.wikipedia.org/wiki/ArnoldSchwarzenegger#cite\\_note-mrever-10](http://en.wikipedia.org/wiki/ArnoldSchwarzenegger#cite_note-mrever-10))
124. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA (2008) Body mass index and mortality in heart failure: a meta-analysis. *Am Heart J* 156:13–22
125. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY (2005) Reverse epidemiology: a spurious hypothesis or a hardcore reality? *Blood Purif* 23:57–63
126. Clerico A, Del Ry S, Giannessi D (2000) Measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. *Clin Chem* 46:1529–1534
127. Apple FS M, Panteghini M, Ravkilde J, Mair J, Wu AHB J, Tate J et al (2005) Quality specifications for B-type natriuretic peptide assays. *Clin Chem* 51:486–493 (On Behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC)
128. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP et al (2007) National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. *Circulation* 116:e95–e98
129. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L et al (2009) Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the Cardio Ormocheck study. *Clin Chem Lab Med* 47:762–768
130. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF et al (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. *J Am Coll Cardiol* 49:1071–1078
131. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC (2008) Nutritional and anti-inflammatory interventions in chronic heart failure. *Am J Cardiol* 101(Suppl 11A):89E–103E
132. Lavie CL, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease. Risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 53:1925–1932
133. Arena R, Lavie CJ (2010) The obesity paradox and outcome in heart failure: is excess bodyweight truly protective? *Future Cardiol* 6:1–6
134. Hedayat M, Mahmoudi MJ, Rose NR, Rezari N (2010) Proinflammatory cytokines in heart failure: double-edged sword. *Heart Fail Rev* 15:543–562
135. Tostain JL, Blanc F (2008) Testosterone deficiency: a common, unrecognized syndrome. *Nat Clin Pract Urol* 5:388–396
136. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. *Hypertension* 46:660–666
137. Chainani-Wu N, Weidner G, Purnell DM, Frenda S, Merritt-Worden T, Kemp C et al (2010) Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. *Am J Cardiol* 105:1570–1576
138. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ (2003) Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. *J Am Coll Cardiol* 41:113–120
139. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med* 350:655–663
140. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA* 293:1609–1616
141. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y (1997) Brain natriuretic peptide predicts mortality in the elderly. *Heart* 77:264–267
142. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW et al (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertension* 47:874–880
143. Nakamura M, Tanaka F, Onoda T, Takahashi T, Sakuma M, Kawamura K et al (2010) Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. *Int J Cardiol* 143:124–129
144. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M et al (1999) Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. *Eur Heart J* 20:1799–1807
145. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J et al (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. *J Am Coll Cardiol* 38:436–442
146. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan heart failure trial (Val-HeFT). *Circulation* 107:1278–1283
147. Koseki Y, Watanabe J, Shinozaki T, Sakuma M, Komaru T, Fukuchi M et al (2003) The CHART Investigators. Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan. *Circ J* 67:431–436
148. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. *Circulation* 106:2913–2918
149. Arakawa N, Nakamura M, Aoki H, Hiramori K (1996) Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. *J Am Coll Cardiol* 27:1561–1656
150. Darbar D, Davidson NC, Gillespie N, Choy AM, Lang CC, Shyr Y et al (1996) Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. *Am J Cardiol* 78:284–287
151. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J et al (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. *J Am Coll Cardiol* 37:1781–1787
152. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al (2002) Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. *Circulation* 105:1760–1763
153. Jernberg T, Stridsberg M, Lindahl B (2002) Usefulness of plasma N-terminal proatrial natriuretic peptide (proANP) as an

- early predictor of outcome in unstable angina pectoris or non-ST-elevation acute myocardial infarction. *Am J Cardiol* 89: 64–66
154. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. *J Am Coll Cardiol* 41:1264–1272
155. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP et al (2004) Italian working group on atherosclerosis, thrombosis, and vascular biology and the associazione nazionale medici cardiologi ospedalieri (ANMCO). N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. *Circulation* 110:128–134
156. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *Br Med J* 330:625
157. Galvani M, Ferrini D, Ottani T (2004) Natriuretic peptides for risk stratification of patients with acute coronary syndromes. *Eur J Heart Fail* 6:327–333
158. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. *Circulation* 120:2177–2187
159. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, et al. (2009) Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. *J Am Coll Cardiol* 54:1599–1606
160. Ryding AD, Kumar S, Worthington A, Burgess D (2009) Prognostic values of brain natriuretic peptide in noncardiac surgery. *Anesthesiology* 111:311–319
161. Kellett J (2004) Prediction of in-hospital mortality by brain natriuretic peptide levels and other independent variables in acutely ill patients with suspected heart disease. *Can J Cardiol* 20:686–690
162. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart association task force on practice guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. *Circulation* 112:e154–e235
163. Lavie CJ, Milani RV, Ventura HO (2010) Body composition and heart failure prevalence and prognosis: getting to the fat of the matter in the “obesity paradox”. *Mayo Clin Proc* 85:605–608
164. Barabási AL (2009) Scale-free networks: a decade and beyond. *Science* 325:412–413
165. Barabási AL (2007) Network medicine—From obesity to the “diseasome”. *N Engl J Med* 357:404–407
166. Goh KI, Cusik ME, Valle D, Childs B, Vidal M, Barabási AL (2007) The human disease network. *Proc Natl Acad Sci USA* 104:8685–8690
167. Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, Barabási AL (2008) The implications of human metabolic network topology for disease comorbidity. *Proc Natl Acad Sci USA* 105:9880–9885
168. Rosen R (2000) *Essays on life itself*. Columbia University Press, New York, pp 306–307
169. Sugisawa T, Kishimoto I, Kokubo Y, Nagumo A, Makino H, Miyamoto Y, Yoshimasa Y (2010) Visceral fat is negatively associated with B-type natriuretic peptide levels in patients with advanced type 2 diabetes. *Diabetes Res Clin Pract* 89:174–180